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Birth size of a woman has been positively associated with her breast cancer risk, particularly before menopause, but no study has
investigated neonatal growth in relation to this risk. We conducted a case–control study nested within a population-based cohort of
women, born in Sweden between 1901 and 1961, covering all 405 breast cancer patients and 1081 age- and hospital-matched
controls, who were born after newborn charts became available. Compared to neonates who lost o200g after birth and grew at a
rate o25gday
 1 after reaching postnatal weight nadir (ie, the minimum, before starting to regain weight), those who either lost
X200g after birth or grew X25gday
 1 after nadir, or both, were at an approximately 50% increased breast cancer risk. The excess
risk was striking and statistically significant among women below 50 years of age, but was not evident among older women.
Immediate postnatal weight loss (an indicator of water loss, likely to reflect water retention associated with pregnancy hormones) as
well as neonatal weight gain rate after the nadir (known to reflect growth hormone levels) was significantly positively associated with
premenopausal breast cancer risk.
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There is much evidence that birth size of women influences their
breast cancer risk (Michels and Xue, 2006; Park et al, 2008),
particularly before menopause (World Cancer Research Fund/
American Institute for Cancer Research, 2007). No study, however,
has investigated neonatal growth in relation to breast cancer
risk, even though neonatal growth could be of particular
importance, as it is strongly associated with neonatal IGF-1 levels
(Albertsson-Wikland et al, 1998; Ogilvy-Stuart et al, 1998; Hikino
et al, 2001; Skalkidou et al, 2003). IGF-1 levels, which could track
through life, have been associated with breast cancer risk,
particularly premenopausal breast cancer risk (Renehan et al,
2004; Fletcher et al, 2005; Rinaldi et al, 2006).
Evaluating neonatal growth is complicated because weight
declines during the first few days after birth, mostly because of
water loss, before starting to increase (Macdonald et al, 2003). The
decline is likely to reflect the extent of water retention by the
newborn at the time of delivery, under the influence of pregnancy
hormones, including oestrogens (Stachenfeld and Keefe, 2002;
Gomella et al, 2004; Stachenfeld and Taylor, 2004). The rate of
weight gain after the nadir is influenced by growth factors,
notably the IGF system and its determinants (Albertsson-Wikland
et al, 1998; Ogilvy-Stuart et al, 1998; Hikino et al, 2001; Skalkidou
et al 2003).
We have investigated neonatal growth in relation to breast
cancer in adult life by a case–control study nested within a
population-based cohort of Swedish women.
MATERIALS AND METHODS
Participants
In Sweden, all residents have equal access to the governmental
health-care system, and because there is essentially no private
in-patient treatment, hospital services are population-based.
Moreover, since 1 January 1947, all residents are assigned an
individually unique nine digit national registration number,
which contains information on the date of birth and the county
in which the individual resided in 1947 or the county of birth for
those born in 1947 or later. This number allows linkage with
several Swedish registries, including the Swedish National Cancer
Registry (Lunde et al, 1980).
In the mid-1990s, we studied the intrauterine environment in
relation to breast cancer risk in the offspring using information
from a cohort of women who had been born in one of the five
participating hospitals in the Uppsala-O ¨rebro Health Care Region
from 1874 through 1961 and who had survived at least until
1 January 1958, when the Swedish National Cancer Registry was
established (Ekbom et al, 1997). In that study, a total of 1068 cases
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ywere diagnosed until 1994 and 2727 controls were included
(Ekbom et al, 1997).
For this study, we retrieved newborn charts with information on
postnatal growth of neonates until their discharge. The maternity
wards in the five hospitals started to use newborn charts at
different calendar periods, and so newborn charts were available
for 406 of the 1068 eligible case patients and for 1083 of the 2727
eligible controls, all born from 1901 onwards. Because extreme
prematurity has been associated with breast cancer risk (Ekbom
et al, 2000), we excluded babies born before 32 weeks of gestation
(one case and two controls), leaving 405 cases and 1081 controls.
Of the former, 90 were below the age of 40 years, 168 were aged
40–49 years, 119 were aged 50–59 years, whereas 28 were aged
60–68 years. The corresponding numbers among controls were
245, 485, 290, and 61 women. In our sample, older women are
underrepresented among cases because the National Cancer
Registry began in 1958, when many older women belonged to
cohorts born before the linked neonatal records became available.
The ratio of controls to cases is lower among women 50 years of
age or above at breast cancer diagnosis. Thus, among women
below the age of 50 years, the control to case ratio is 2.8 (730/258),
whereas among older women it is 2.4 (351/147). This is because in
the earlier years, when older women were born, the likelihood of
recording weight changes of newborns was much lower (when an
index case was removed because of missing records, the
corresponding controls were also removed, whereas if one or
two controls had missing records, the remaining control(s) would
suffice for retaining the corresponding case in the analysis).
At the birth of our subjects, breastfeeding predominated for
newborns and the mother and child were usually discharged when
the baby reached its birth weight. Generally, newborns lose weight
during the first week and then gain weight (Macdonald et al, 2003).
To examine whether these two different phases of postnatal pattern
of growth were associated with subsequent risk of breast cancer,
we determined maximum postnatal weight loss (defined as (birth
weight) (the lowest weight in the hospital)) and the rate of growth
since the nadir (defined as (weight at discharge weight at nadir)/
(day at discharge day at nadir)).
On the basis of the literature (Macdonald et al, 2003) we have
created the following five mutually exclusive categories: (a)
neonates who remained at the maternity wards for more than 21
days without regaining their birth weight–these neonates were
analysed separately because their weight loss and gain were
unusual; (b) neonates with a maximum weight loss of o200g and
growth rate after nadir o25gday
 1; (c) neonates with a maximum
weight loss of X200g and growth rate after nadir o25gday
 1; (d)
neonates with a maximum weight loss of o200g and growth rate
after nadir X25gday
 1 and (e) neonates with a maximum
postnatal weight loss of X200g and growth rate after nadir
X25gday
 1. All neonates in categories b–e remained at the
maternity wards for a maximum of 21 days. The weight loss cutoff
of 200g was a round figure derived from the 6.6% reported to be
the median percent of birth weight loss for breastfed children
(Macdonald et al, 2003), and so with birth weight around 3000g,
we have 3000g*0.066C200g. The cutoff for the daily rate of
growth after nadir was rounded at 25gday
 1, as the reported
median time for birth weight recovery among breastfed children is




The statistical analyses were undertaken by modelling the data
through conditional logistic regression using PROC PHREG of the
SAS statistical software (version 9, SAS Institute, Cary, NC, USA).
Covariates adjusted in the analysis included maternal age (in years
as a continuous variable), maternal socioeconomic status
(low, medium, and high as an ordinal variable), maternal parity
(1, 2, and X3 as categorical indicator variables), pregnancy
toxaemia (yes/no), neonatal jaundice (yes/no), twin membership
(singleton, monozygotic, and dizygotic as categorical indicator
variables), and birth weight (o2500, 2500–2999, 3000–3499,
3500–3999, and X4000g as categorical indicator variables).
The study was approved by the Institutional Review Boards of
the Karolinska Institutet, Sweden, the Harvard School of Public
Health, USA, and the US Department of Defense.
RESULTS
Table 1 presents the maternal and perinatal characteristics of
breast cancer patients and their control women (matched to the
cases with variable matching ratio). As reported earlier (Ekbom
et al, 1997), neonatal jaundice is more common among cases,
whereas maternal toxaemia is more common among controls. In
this data set, the association between birth size and breast cancer
risk was weak and statistically non-significant (Ekbom et al, 1997).
Spearman’s correlation coefficients of birth weight with maxi-
mum weight loss and daily weight gain since nadir were 0.48
(Po0.0001) and 0.02 (P¼0.55), respectively. In these bivariate and
possibly confounded patterns, neonatal weight loss appears more
pronounced among cases than among controls. There is also some
evidence that weight gain after nadir is more pronounced among
breast cancer patients below the age of 50 years compared with
controls.
After controlling for confounding through conditional logistic
regression, we found no evidence that neonates who did not
conform to the usual growth pattern are at different breast cancer
risk when compared with the reference category of neonates who
lost less than 200g after birth and grew at a rate less than
25gday
 1 after nadir (Table 2). In contrast, however, neonates
who lost X200g after birth, or neonates who grew at a rate of
X25gday
 1 after nadir, or neonates with both of these growth
pattern characteristics were at an approximately 50% increased
risk in later life when compared with the reference category. The
excess risk was evident and statistically significant exclusively
among women below the age of 50 years, who were presumably
premenopausal at breast cancer diagnosis. As, in our data, women
were designated as pre- or postmenopausal relying only on their
age, we have evaluated whether there is an interaction between age
and growth pattern with respect to breast cancer risk, and the
results were of borderline significance (PB0.06).
DISCUSSION
In our case–control study, nested within a well-defined popula-
tion-based cohort of Swedish women, we have found evidence that
immediate postnatal weight loss of the newborn, as well as the
neonate’s weight gain rate after reaching a nadir of postnatal
weight, are significantly positively associated with breast cancer
risk among women below the age of 50 years. As indicated in the
Introduction, in the light of the literature, we considered the
immediate postnatal weight loss as an indicator of water loss,
probably reflecting water retention caused by pregnancy hor-
mones, and the postnadir rate of growth as an indicator of higher
levels of growth hormones, particularly IGF-1.
We interpret our findings as indicating that higher levels of
pregnancy hormones and growth hormones during the immediate
postnatal period, particularly IGF-1, play an important role in
premenopausal breast cancer risk several decades later.
No association of postnatal growth pattern with breast cancer
risk was evident among women 50 years of age or above, and
presumably postmenopausal who, however, were relatively few in
this study sample. Besides the numbers, it is also possible that any
effect of perinatal factors on risk is gradually diluted as additional
adult life breast cancer risk factors are introduced, in line with the
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yconclusion of a major review that birth weight is positively
associated with breast cancer risk mostly among premenopausal
women (World Cancer Research Fund/American Institute for
Cancer Research, 2007). Age at and type of menopause (natural or
induced) are important postmenopausal risk factors, and pre- and
postmenopausal breast cancer are frequently treated as distinct
entities in studies focusing on their hormonal and non-hormonal
aetiology (Hankinson et al, 2008).
Our study makes use of the unusual opportunities available
in Sweden for linking population-based databases and registries.
The nested case–control study design retains the advantages
of a cohort study in terms of minimisation of information and
selection bias. Exclusions were simply on the basis of the
availability of linked newborn charts. The sample contained many
more women below the age of 50 years (presumably premeno-
pausal) than older women (presumably postmenopausal), and
Table 1 Maternal and perinatal characteristics of 405 breast cancer cases and 1081 matched control subjects
All women Women o50 years old Women X50 years old
Cases Controls Cases Controls Cases Controls
N¼405 N¼1081 N¼258 N¼730 N¼147 N¼351
No (%) No (%) No (%) No (%) No (%) No (%)
Maternal age (years)
o24 125 30.9 385 35.6 77 19.0 257 23.8 48 11.9 128 11.8
25–34 213 52.6 524 48.5 138 34.1 345 31.9 75 18.5 179 16.6
35+ 67 16.5 172 15.9 43 10.6 128 11.8 24 5.9 44 4.1
Maternal socioeconomic status
Low 303 74.8 804 74.4 190 46.9 543 50.2 113 27.9 261 24.1
Medium 91 22.5 199 18.4 61 15.1 132 12.2 30 7.4 67 6.2
High 11 2.7 78 7.2 7 1.7 55 5.1 4 1.0 23 2.1
Maternal parity
1 170 42.0 499 46.2 110 27.2 343 31.7 60 14.8 156 14.4
2 107 26.4 283 26.2 70 17.3 204 18.9 37 9.1 79 7.3
3+ 128 31.6 299 27.7 78 19.3 183 16.9 50 12.3 116 10.7
Maternal toxaemia
No 397 98.0 1036 95.8 251 62.0 703 65.0 146 36.0 333 30.8
Yes 8 2.0 45 4.2 7 1.7 27 2.5 1 0.2 18 1.7
Neonatal jaundice
No 380 93.8 1045 96.7 248 61.2 716 66.2 132 32.6 329 30.4
Yes 25 6.2 36 3.3 10 2.5 14 1.3 15 3.7 22 2.0
Twin membership
No 398 98.3 1068 98.8 253 62.5 723 66.9 145 35.8 345 31.9
Yes 7 1.7 13 1.2 5 1.2 7 0.6 2 0.5 6 0.6
Birth weight (g)
o2500 14 3.5 42 3.9 8 2.0 26 2.4 6 1.5 16 1.5
2500–2999 57 14.1 157 14.5 36 8.9 108 10.0 21 5.2 49 4.5
3000–3499 145 35.8 408 37.7 85 21.0 279 25.8 60 14.8 129 11.9
3500–3999 143 35.3 338 31.3 101 24.9 224 20.7 42 10.4 114 10.5
X4000 46 11.4 136 12.6 28 6.9 93 8.6 18 4.4 43 4.0
Hospital stay X21 days
No 372 91.9 1018 94.2 244 60.2 692 64.0 128 31.6 326 30.2
Yes 33 8.1 63 5.8 14 3.5 38 3.5 19 4.7 25 2.3
Maximum weight loss (g) after delivery (among normal discharge)
o200 73 19.6 247 24.3 48 19.7 162 23.4 25 19.5 85 26.1
X200 299 80.4 771 75.7 196 80.3 530 76.6 103 80.5 241 73.9
Weight gain (gday
 1) after reaching nadir (among normal discharge)
o25 183 49.2 512 50.3 119 48.8 371 53.6 64 50.0 141 43.3
X25 189 50.8 506 49.7 125 51.2 321 46.4 64 50.0 185 56.7
Weight change after delivery (combining previous two variables)
o200g/o25gday
 1 33 8.9 131 12.9 19 7.8 96 13.9 14 10.9 35 10.7
X200g/o25gday
 1 150 40.3 381 37.4 100 41.0 275 39.7 50 39.1 106 32.5
o200g/X25gday
 1 40 10.8 116 11.4 29 11.9 66 9.5 11 8.6 50 15.3
X200g/X25gday
 1 149 40.1 390 38.3 96 39.3 255 36.8 53 41.4 135 41.4
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yso there should be more confidence in the associations found
among the former than on their absence among presumably
postmenopausal women. In the base of the study, on which we
relied, birth size indicators (birth weight, birth length, and
placental weight) were very weakly positively related to risk,
although mutual adjustment of these indicators tended to increase
the positive trends (Ekbom et al, 1997). However, when a true but
weak association is investigated in many studies, some are bound
to generate non-significant or even null results (Michels and Xue,
2006; Park et al, 2008). We had no information about adult life
risk factors for breast cancer (e.g., age at menarche), but even
if associations of such factors with postnatal growth were to
be found, they would probably have been placed as intermediates
(which should not be controlled for) rather than as confounders
(which should). There are, of course, several other risk factors
(e.g., age at the first pregnancy, parity, hormone replacement
therapy, and so on), which could not act as confounders, as they
are unlikely to be related to postnatal growth.
It has been postulated that the likelihood of breast cancer
depends on the number of mammary stem cells, which is
determined in early, including intrauterine life, as well as on the
early postnatal levels of growth-enhancing mammotropic hormones,
which affect the replication rate of such stem cells (Trichopoulos,
1990; Adami et al, 1995; Trichopoulos et al, 2005, 2008). Birth size is
known to influence breast cancer risk (Michels and Xue, 2006; Park
et al, 2008), and there is compelling evidence that periadolescent
growth (Ahlgren et al, 2004) and adult height (Tretli 1989; World
Cancer Research Fund/American Institute for Cancer Research,
2007) are also associated with this risk. Using haematopoietic stem
cells as probable correlates of the difficult-to-measure mammary
stem cells, the size of their pool was positively associated with both
umbilical cord growth hormones and birth weight (Savarese et al,
2007; Strohsnitter et al, 2008). No earlier investigation, however, has
examined postnatal growth in relation to breast cancer risk, even
though postnatal growth is rapid and the mammary gland is far
from being fully differentiated (Russo and Russo, 1987).
The IGF system is associated with both breast cancer risk
(Renehan et al, 2004; Fletcher et al, 2005; Rinaldi et al, 2006)
and postnadir growth (Albertsson-Wikland et al, 1998; Ogilvy-
Stuart et al, 1998; Hikino et al, 2001; Skalkidou et al, 2003),
and could therefore plausibly explain the association of postnadir
growth with this risk. Our explanation of the association of
immediate postnatal weight reduction with breast cancer risk
invokes higher levels of pregnancy hormones, including oestro-
gens, on the basis of well-known properties of these hormones
(Stachenfeld and Keefe, 2002; Gomella et al, 2004; Stachenfeld
and Taylor, 2004).
Replication of our results is clearly necessary. The examination
of the possible differential association of neonatal growth with
hormone-sensitive and hormone-insensitive breast cancer, as
reflected for instance in hormone receptor expression (Duffy,
2006; Hankinson et al, 2008), would also be of importance. Such
information was not available in our database. Animal models
have provided valuable information with respect to early life
exposures and breast cancer risk (Hilakivi-Clarke et al, 1994;
Hilakivi-Clarke and de Assis, 2006) and could be useful in relation
to postnatal growth.
The findings of this study are intriguing and the apparent
magnitude of effect (the twofold increases in premenopausal breast
cancer risk for essentially dichotomous contrasts) indicates that
the phenomenon is of considerable importance. Confidence limits,
however, are wide and the absence of evidence for even additive
interaction is of some concern.
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